The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

NCT01923428 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

356

Enrollment

INDUSTRY

Sponsor class

Conditions

Constipation Predominant Irritable Bowel Syndrome

Interventions

DRUG: AZD1722
DRUG: Placebo

Sponsor

Ardelyx